Phytochemicals as prototypes for pharmaceutical leads towards drug development against diabetic cardiomyopathy

Current Pharmaceutical Design

Volumn 22, Issue 20, 2016, Pages 3058-3070

  Ojha, Shreesh ^a   Kurdi, Amani ^b   Sadek, Bassem ^a   Kaleem, M ^a   Cai, Lu ^c   Kamal, M A ^d,e   Rajesh, Mohanraj ^a  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^b Biuret Arab University   (Lebanon)

^c University of Louisville School of Medicine   (United States)

^d KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^e Enzymoics   (Australia)

Author keywords

Apoptosis; Cardiac function; Cardiovascular complications; Diabetes mellitus; Diabetic cardiomyopathy; Fibrosis; Inflammation; Oxidative stress; Phytochemicals

Indexed keywords

ASTRAGALUS POLYSACCHARIDE; BERBERINE; BREVISCAPINE; CAFFEIC ACID; CAFFEIC ACID PHENETHYL ESTER; CANNABIDIOL; CANNABIS; CARDIOVASCULAR AGENT; CHELERYTHRINE; CURCUMIN; DAIDZEIN; EPIGALLOCATECHIN GALLATE; FERULIC ACID; GALLIC ACID; GENEISTEIN; GINKGOLIDE B; GYPENOSIDE; LUTEOLIN; PLANT MEDICINAL PRODUCT; POLYSACCHARIDE; PYCNOGENOL; RESVERATROL; SULFORAPHANE; TANSHINONE IIA; TOTAL ARALOSIDE OF ARALIA ELATA SEEM; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARALIA; ARALIA ELATA; ARTICLE; ASTRAGALUS MEMBRANACEUS; BERBERIS VULGARIS; BRASSICA OLERACEA; CHELIDONIUM; CHINESE MEDICINE; CORYLOPSIS PAUCIFLORA; CURCUMA LONGA; DIABETIC CARDIOMYOPATHY; DIABETIC PATIENT; DRUG BIOAVAILABILITY; DRUG DISPOSITION; ERIGERON BREVISCAPUS; FERULA ASFOETIDA; GENETIC POLYMORPHISM; GINKGO BILOBA; GLUCOTOXICITY; GLUCURONIDATION; GLYCEMIC CONTROL; GYNOSTEMMA PENTAPHYLLUM; HEART FUNCTION; HEART INJURY; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART PROTECTION; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FUNCTION; NITRATIVE STRESS; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PHASE 3 CLINICAL TRIAL (TOPIC); PINIS PINASTER; PRIORITY JOURNAL; QUALITY OF LIFE; SALVIA MILTIORRHIZA; TEA; TOMATO; VITIS VINEFERA; CHEMISTRY; COMPLICATION; DRUG DEVELOPMENT; HUMAN; SYNTHESIS;

DIABETIC CARDIOMYOPATHIES; DRUG DISCOVERY; HUMANS; PHYTOCHEMICALS;

EID: 84973635825     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666160322145255     Document Type: Article

References (119)

1. Boyle JP, Honeycutt AA, Narayan KMV, et al. Projection of diabetes burden through 2050: Impact of changing demography and disease prevalence in the U.S. Diabetes Care 2001; 24: 1936-40.
2. Wang CCL, Reusch JEB. Diabetes and cardiovascular disease: Changing the focus from glycemic control to improving long-term survival. Am J Cardiol 2012; 110 (Supp 9): S58-68.
3. Bertoni AG, Hundley WG, Massing MW, Bonds DE, Burke GL, Goff DC. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 2004; 27: 699-703.
4. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972; 30: 595-602.
5. Aragno M, Mastrocola R, Medana C, et al. Oxidative stressdependent impairment of cardiac-specific transcription factors in experimental diabetes. Endocrinology 2006; 147: 5967-74.
6. Devereux RB, Roman MJ, Paranicas M, et al. Impact of diabetes on cardiac structure and function: The strong heart study. Circulation 2000; 101: 2271-6.
7. Pacher P, Szabo C. Role of the peroxynitrite-poly(ADP-Ribose) polymerase pathway in human disease. Am J Pathol 2008; 173: 2- 13.
8. Varga ZV, Giricz ZN, Liaudet L, Hasko G, Ferdinandy P, Pacher P. Interplay of oxidative, nitrosative/nitrative stress, inflammation, cell death and autophagy in diabetic cardiomyopathy. Biochim Biophys Acta 2015; 1852: 232-42.
9. Cai L, Kan YJ. Oxidative stress and diabetic cardiomyopathy: a brief review. Cardiovasc Toxicol 2001; 1: 181-93.
10. Rajesh M, Mukhopadhyay P Bátkai S, et al. Xanthine oxidase inhibitor allopurinol attenuates the development of diabetic cardiomyopathy. J Cell Mol Med 2009; 13: 2330-41.
11. Falcão-Pires I, Leite-Moreira A. Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment. Heart Fail Rev 2012; 17: 325-44.
12. Pacher P, Liaudet L, Soriano FG, Mabley JG, Szabó É, Szabó C. The role of poly(ADP-Ribose) polymerase activation in the development of myocardial and endothelial Dysfunction in diabetes. Diabetes 2002; 51: 514-21.
13. Cai L, Kang YJ. Cell death and diabetic cardiomyopathy. Cardiovasc Toxicol 2003; 3: 219-28.
14. Bodiga V, Eda S, Bodiga S. Advanced glycation end products: role in pathology of diabetic cardiomyopathy. Heart Fail Rev 2014; 19: 49-63.
15. Lacombe VA, Viatchenko-Karpinski S, Terentyev D, et al. Mechanisms of impaired calcium handling underlying subclinical diastolic dysfunction in diabetes, Am J Physiol Regul Integr Comp Physiol 2007; 293: R1787-97.
16. Belke DD, Dillmann WH. Altered cardiac calcium handling in diabetes. Curr Hypertens Re 2004; 6: 424-9.
17. Zarain-Herzberg A, García-Rivas G, Estrada-Avilés R. Regulation of SERCA pumps expression in diabetes. Cell Calcium 2014; 56: 302-10.
18. Lebeche D, Davidoff AJ, Hajjar RJ. Interplay between impaired calcium regulation and insulin signaling abnormalities in diabetic cardiomyopathy. Nat Clin Pract Cardiovasc Med 2008; 5: 715-24.
19. Van de Weijer T, Schrauwen-Hinderling VB, Schrauwen P. Lipotoxicity in type 2 diabetic cardiomyopathy. Cardiovasc Res 2011; 92: 10-8.
20. Park TS, Hu Y, Noh HL, et al. Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. J Lipid Res 2008; 49: 2101-12.
21. Finck BN, Han X, Courtois M, Aimond F, Nerbonne JM, Kovacs A. A critical role for PPARα-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: Modulation by dietary fat content. Proc Natl Acad Sci USA 2003; 100: 1226-31.
22. Park TS, Goldberg IJ. Sphingolipids, lipotoxic cardiomyopathy, and cardiac failure. Heart Fail Clin 2012; 8: 633-41.
23. Langeveld M, Aerts JMFG. Glycosphingolipids and insulin resistance. Prog Lipid Res 2009; 48: 196-205.
24. Drosatos K, Schulze PC. Cardiac lipotoxicity: molecular pathways and therapeutic implications. Curr Heart Fail Rep 2013; 10: 109- 21.
25. Dirkx E, Schwenk RW, Glatz JFC, Luiken, JJ.P, van Eys GJJM. High fat diet induced diabetic cardiomyopathy. Prostaglandins Leukot Essent Fatty Acids 2011; 85: 219-25.
26. Mori J, Patel VB, Abo Alrob O, et al. Angiotensin 1-7 ameliorates diabetic cardiomyopathy and diastolic Dysfunction in db/db mice by reducing lipotoxicity and inflammation. Circ Heart Fail 2014; 7: 327-39.
27. Rajesh M, Bátkai S, Kechrid M, et al. Cannabinoid 1 receptor promotes cardiac dysfunction, oxidative stress, inflammation, and fibrosis in diabetic cardiomyopathy. Diabetes 2012; 61: 716-27.
28. Bland JS. Phytonutrition, phytotherapy, and phytopharmacology. Altern Ther Health Med 1996; 2: 73-6.
29. Morejohn LC, Fosket DE. The biochemistry of compounds with anti-microtubule activity in plant cells. Pharmacol Ther 1991; 51: 217-30.
30. Dong WC. Determination of total aralosides in Aralia mandshurica grown in Jilin and Liaoning Provinces. Zhong Yao Tong Bao 1986; 11: 44-6.
31. Xi S, Zhou G, Zhang X, Zhang W, Cai L, Zhao, C. Protective effect of total aralosides of Aralia elata (Miq) Seem (TASAES) against diabetic cardiomyopathy in rats during the early stage, and possible mechanisms. Exp Mol Med 2009; 41: 538-47.
32. Chen W, Li YM, Yu MH. Effects of astragalus polysaccharides on chymase, angiotensin-converting enzyme and angiotensin II in diabetic cardiomyopathy in hamsters. J Int Med Res 2000; 35: 873- 7.
33. Chen W, Li YM, Yu MH. Astragalus polysaccharides inhibited diabetic cardiomyopathy in hamsters depending on suppression of heart chymase activation. J Diabetes Complications 2010; 24: 199- 208.
34. Chen W, Chen W, Xia Y, et al. Therapy with astragalus polysaccharides rescues lipotoxic cardiomyopathy in MHC-PPARα mice. Mol Biol Rep 2013; 40: 2449-59.
35. Ahmad S, Wei CC, Tallaj J, et al. Chymase mediates angiotensin- (1-12) metabolism in normal human hearts. J Am Soc Hypertens 2013; 7: 128-36.
36. Miyazaki M, Takai S, Jin D, Muramatsu M. Pathological roles of angiotensin II produced by mast cell chymase and the effects of chymase inhibition in animal models. Pharmacol Ther 2006; 112: 668-76.
37. Yahiro E, Miura S, Imaizumi S, UeharaY, Saku K. Chymase inhibitors. Curr Pharm Des 2013; 19: 3065-71.
38. Chen W, Xia Y, Zhao X, Wang H, Yu M, Li Y. The critical role of Astragalus polysaccharides for the improvement of PPARalphamediated lipotoxicity in diabetic cardiomyopathy. PLoS One 2012; 7: e45541.
39. Mokhber-Dezfuli N, Saeidnia S, Gohari A, Kurepaz- Mahmoodabadi M. Phytochemistry and pharmacology of berberis species. Pharmacogn Rev 2014; 8: 8-15.
40. Li Z, Geng YN, Jiang JD, Kong WJ. Antioxidant and anti- Inflammatory activities of berberine in the treatment of diabetes mellitus. Evid Based Complement Alternat Med 2014; 2014: 289264. doi: 10.1155/2014/289264.
41. Wang LH, Li XL, Li Q, et al. Berberine alleviates ischemic arrhythmias via recovering depressed Ito and ICa currents in diabetic rats. Phytomedicine 2012; 19: 206-10.
42. Chen XJ, Cheng DY, Yang L, Xia XQ, Guan J. Effect of breviscapine on fractalkine expression in chronic hypoxic rats. Chin Med J (Engl) 2006; 119: 1465-8.
43. Wang M, Zhang Wb, Zhu Jh, Fu GS, Zhou BQ. Breviscapine ameliorates cardiac dysfunction and regulates the myocardial Ca2+-cycling proteins in streptozotocin-induced diabetic rats. Acta Diabetol 2010; 47: 209-18.
44. Brittsan AG, Kranias EG. Phospholamban and cardiac contractile function. J Mol Cell Cardiol 2000; 32: 2131-9.
45. Wang M, Zhang WB, Zhu JH, Fu GS, Zhou BQ. Breviscapine ameliorates hypertrophy of cardiomyocytes induced by high glucose in diabetic rats via the PKC signaling pathway. Acta Pharmacol Sin 2009; 30: 1081-91.
46. Liu X, Qi F, Wu W. Effect of intervention in the diacylglycerolprotein kinase C signaling pathway on JNK1 expression and its downstream signaling in diabetic cardiomyopathy. Mol Med Rep 2014; 9: 979-84.
47. Ma Y, Li H, Guan S. Enhancement of the oral bioavailability of breviscapine by nanoemulsions drug delivery system. Drug Dev Ind Pharm 2015; 41: 177-82.
48. Zhang P, Tang Y, Li NG, Zhu Y, Duan JA. Bioactivity and chemical synthesis of caffeic acid phenethyl ester and its derivatives. Molecules 2014; 19: 16458-76.
49. Park SH, Min TS. Caffeic acid phenethyl ester ameliorates changes in IGFs secretion and gene expression in streptozotocin-induced diabetic rats. Life Sci 2006; 78: 1741-7.
50. Okutan H, Ozcelik N, Ramazan Yilmaz H, Uz E. Effects of caffeic acid phenethyl ester on lipid peroxidation and antioxidant enzymes in diabetic rat heart. Clin Biochem 2005; 38: 191-6.
51. Chao PC, Hsu CC, Yin MC. Anti-inflammatory and anticoagulatory activities of caffeic acid and ellagic acid in cardiac tissue of diabetic mice. Nutr Metab (Lond) 2009; 6: 33.
52. Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R. Nonpsychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 2009; 30: 515-27.
53. Horvath B, Mukhopadhyay P, Hasko G, Pacher P. The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications. Am J Pathol 2012; 180: 432- 42.
54. Rajesh M, Mukhopadhyay P, Batkai S, et al. Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol 2010; 56: 2115-25.
55. Durst R, Danenberg H, Gallily R, et al. Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury, Am J Physiol Heart Circ Physiol 2007; 293: H3602-7.
56. El-Remessy AB, Al-Shabrawey M, Khalifa Y, Tsai NT, Caldwell RB, Liou GI. Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. Am J Pathol 2006; 168: 235-44.
57. Wheal AJ, Cipriano M, Fowler CJ, Randall MD, O'Sullivan SE. Cannabidiol improves vasorelaxation in zucker diabetic fatty rats through cyclooxygenase activation. J Pharmacol Exp Ther 2014; 351: 457-66.
58. Koehler Jr, Amato MP, Oreja-Guevara C, Lycke J. Clinical case reviews in multiple sclerosis spasticity: experiences from around Europe. Expert Rev Neurother 2013; 13: 61-6.
59. Yang G, Lee K, Lee MH, Kim SH, Ham IH, Choi HY. Inhibitory effects of Chelidonium majus extract on atopic dermatitis-like skin lesions in NC/Nga mice. J Ethnopharmacol 2011; 138: 398-403.
60. Wang PQ, Yin ZH, Kang WY. Advance in studies on pharmacological activities of chelerythrine. Zhongguo Zhong Yao Za Zhi 2013; 38: 2745-9.
61. Herbert JM, Augereau JM, Gleye J, Maffrand JP. Chelerythrine is a potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun 1990; 172: 993-9.
62. Davidoff AJ, Davidson MB, Carmody MW, Davis ME, Ren J. Diabetic cardiomyocyte dysfunction and myocyte insulin resistance: role of glucose-induced PKC activity. Mol Cell Biochem 2004; 262: 155-63.
63. Sheetz MJ, Aiello LP, Davis MD, Danis R, Bek T, Cunha-Vaz J, et al. Oral PKCbeta inhibitor ruboxistaurin on vision Loss in two phase 3 studies. Invest Ophthal Vis Sci 2013; 54: 1750-7.
64. Connelly KA, Kelly DJ, Zhang Y, et al. Inhibition of protein cinase C-CCby ruboxistaurin preserves cardiac function and reduces extracellular matrix production in diabetic cardiomyopathy. Circ Heart Fail 2009; 2: 129-37.
65. Zhang DW, Fu M, Gao SH, Liu JL. Curcumin and diabetes: a systematic review. Evid Based Complement Alternat Med 2013; 2013: 636053.
66. Soetikno V, Sari FR, Sukumaran, V, et al. Curcumin prevents diabetic cardiomyopathy in streptozotocin-induced diabetic rats: Possible involvement of PKC-MAPK signaling pathway. Eur J Pharm Sci 2012; 47: 604-14.
67. Yu W, Wu J, Cai F, et al. Curcumin alleviates diabetic cardiomyopathy in experimental diabetic rats. PLoS One 2012; 7: e52013.
68. Pan Y, Wang, Y, Zhao Y, et al. Inhibition of JNK phosphorylation by a novel curcumin analog prevents high glucose-induced inflammation and apoptosis in cardiomyocytes and the development of diabetic cardiomyopathy. Diabetes 2014; 63: 3497- 511.
69. Wang Y, Zhou S, Sun W, et al. Inhibition of JNK by novel curcumin analog C66 prevents diabetic cardiomyopathy with a preservation of cardiac metallothionein expression, Am J Physiol Endocrinol Metab 2014; 306: E1239-47.
70. Prasad S, Tyagi AK, Aggarwal BB. Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice. Cancer Res Treat 2014; 46: 2-18.
71. Esaki H, Kawakishi S, Morimitsu Y, Osawa T. New potent antioxidative -dihydroxyisoflavones in fermented Japanese soybean products. Biosci Biotechnol Biochem 1999; 63: 1637-9.
72. Gil-Izquierdo A, Penalvo JL, Gil JI, et al. Soy isoflavones and cardiovascular disease epidemiological, clinical and -omics perspectives. Curr Pharm Biotechnol 2012; 13: 624-31.
73. Douglas CC, Johnson SA, Arjmandi BH. Soy and its isoflavones: the truth behind the science in breast cancer. Anticancer Agents Med Chem 2013; 13: 1178-87.
74. Hintz KK, Ren J. Phytoestrogenic isoflavones daidzein and genistein reduce glucose-toxicity-induced cardiac contractile dysfunction in ventricular myocytes. Endocr Res 2004; 30; 215-23.
75. Ajmani P, Yadav HN, Singh M, Sharma PL. Possible involvement of caveolin in attenuation of cardioprotective effect of ischemic preconditioning in diabetic rat heart. BMC Cardiovasc Disord 2011; 11: 43.
76. Akiyama T, Ishida J, Nakagawa S, et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 1987; 262: 5592-5.
77. Kim HS, Quon MJ, Kim JA. New insights into the mechanisms of polyphenols beyond antioxidant properties; lessons from the green tea polyphenol, epigallocatechin 3-gallate. Redox Biol 2014; 2: 187-95.
78. Yu L, Zhao Y, Fan Y, Wang M, Xu S, Fu G. Epigallocatechin-3 gallate, a green tea catechin, attenuated the downregulation of the cardiac gap junction induced by high glucose in neonatal rat cardiomyocytes. Cell Physiol Biochem 2010; 26: 403-12.
79. Liu J, Tang Y, Feng Z, Long J. Epigallocatechin-3-gallate attenuated myocardial mitochondrial dysfunction and autophagy in diabetic Goto - Kakizaki rats. Free Radic Res 2014; 48: 898-906.
80. Graf E. Antioxidant potential of ferulic acid. Free Radic Biol Med 1992; 13: 435-48.
81. Xu X, Xiao H, Zhao J, Zhao T. Cardioprotective effect of sodium ferulate in diabetic rats. Int J Med Sci 2012; 9: 291-300.
82. Choi R, Kim BH, Naowaboot J, et al. Effects of ferulic acid on diabetic nephropathy in a rat model of type 2 diabetes. Exp Mol Med 2011; 43: 676-83.
83. Liu Y, Carver JA, Calabrese AN, Pukala TL. Gallic acid interacts with alpha-synuclein to prevent the structural collapse necessary for its aggregation. Biochim Biophys Acta 2014; 1844: 1481-5.
84. Patel SS, Goyal GK, Cardioprotective effects of gallic acid in diabetes-induced myocardial dysfunction in rats. Pharmacognosy Res 2011; 3: 239-45.
85. Kleijnen J, Knipschild P. Ginkgo biloba. Lancet 1992; 340: 1136-9.
86. Kim J, Li Q, Fang CX, Ren J. Paradoxical effects of ginkgolide B on cardiomyocyte contractile function in normal and high-glucose environments. Acta Pharmacol Sin 2006; 27: 536-42.
87. Zhao J, Ming Y, Wan Q, et al. Gypenoside attenuates hepatic ischemia/reperfusion injury in mice via anti-oxidative and antiapoptotic bioactivities. Exp Ther Med 2014; 7: 1388-92.
88. Wang XJ, Sun T, Kong L, et al. Gypenosides pre-treatment protects the brain against cerebral ischemia and increases neural stem cells/progenitors in the subventricular zone. Int J Dev Neurosci 2014; 33: 49-56.
89. Ge M, Ma S, Tao, Guan S. The Effect of gypenosides on cardiac function and expression of cytoskeletal genes of myocardium in diabetic cardiomyopathy rats. Am J Chin Med 2009; 37: 1059-68.
90. Ross JA, Kasum CM. Dietary flavonoids: bioavailability, metabolic effects, and safety. Ann Rev Nutr 2002; 22: 19-34.
91. Wang G, Li W, Lu X, Bao P, Zhao X. Luteolin ameliorates cardiac failure in type I diabetic cardiomyopathy. J Diabetes Complications 2012; 26: 259-65.
92. Maimoona A, Naeem I, Saddiqe Z, Jameel K. A review on biological, nutraceutical and clinical aspects of French maritime pine bark extract. J Ethnopharmacol 2011; 133: 261-77.
93. Klimas J, Kmecova J, Jankyova S, et al. Pycnogenol® improves left ventricular function in streptozotocin-induced diabetic cardiomyopathy in rats. Phytother Res 2010; 24: 969-74.
94. Jankyova S, Kmecova J, Cernecka H, et al. Glucose and blood pressure lowering effects of pycnogenol are inefficient to prevent prolongation of QT interval in experimental diabetic cardiomyopathy. Pathol Res Pract 2012; 208: 452-7.
95. Kralova E, Jankyova S, Mucaji P, Gresakova E, Stankovicova T. Pycnogenol and its fractions influence the function of isolated heart in rats with experimental diabetes mellitus. Pathol Res Pract 2015; 211: 156-61.
96. Pangeni R, Sahni JK, Ali J, Sharma S, Baboota S. Resveratrol: review on therapeutic otential and recent advances in drug delivery. Expert Opin Drug Deliv 2014; 11: 1285-98.
97. Chen CY, Jang JH, Li MH, Surh YJ. Resveratrol upregulates heme oxygenase-1 expression via activation of NF-E2-related factor 2 in PC12 cells. Biochem Biophys Res Commun 2005; 331: 993-1000.
98. Borra MT, Smith BC, Denu JM. Mechanism of human SIRT1 activation by resveratrol. J Biol Chem 2005; 280: 17187-95.
99. Sulaiman M, Matta MJ, Sunderesan NR, et al. Resveratrol, an activator of SIRT1, upregulates sarcoplasmic calcium ATPase and improves cardiac function in diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 2010; 298: H833-43.
100. Huang JP, Huang SS, Deng JY, Chang CC, Day YJ, Hung LM. Insulin and resveratrol act synergistically, preventing cardiac dysfunction in diabetes, but the advantage of resveratrol in diabetics with acute heart attack is antagonized by insulin. Free Radic Biol Med 2010; 49: 1710-21.
101. Gao Y, Kang L, Li C, et al. Resveratrol ameliorates diabetesinduced cardiac dysfunction through AT1R-ERK/p38 MAPK signaling pathway. Cardiovasc Toxicol 2016; 16: 130-7.
102. Beaudoin MS, Perry CGR, Arkell AM, et al. Impairments in mitochondrial palmitoyl-CoA respiratory kinetics that precede development of diabetic cardiomyopathy are prevented by resveratrol in ZDF rats. J Physiol 2014; 592: 2519-33.
103. Wang B, Yang Q, Sun YY, et al. Resveratrol-enhanced autophagic flux ameliorates myocardial oxidative stress injury in diabetic mice. J Cell Mol Med 2014; 18: 1599-611.
104. Houghton CA, Fassett RG, Coombes JS. Sulforaphane: translational research from laboratory bench to clinic. Nutr Rev 2013; 71: 709-26.
105. Liu H, Talalay P. Relevance of anti-inflammatory and antioxidant activities of exemestane and synergism with sulforaphane for disease prevention. Proc Natl Acad Sci USA 2013; 110: 19065-70.
106. Cannavino J, Brocca L, Sandri M, Bottinelli R, Pellegrino MA. PGC1alpha over-expression prevents metabolic alterations and soleus muscle atrophy in hindlimb unloaded mice. J Physiol 2014; 592: 4575-89.
107. Bai Y, Cui W, Xin Y, et al. Prevention by sulforaphane of diabetic cardiomyopathy is associated with up-regulation of Nrf2 expression and transcription activation. J Mol Cell Cardiol 2013; 57: 82-95.
108. Zhang Z, Wang S, Zhou S, et al. Sulforaphane prevents the development of cardiomyopathy in type 2 diabetic mice probably by reversing oxidative stress-induced inhibition of LKB1/AMPK pathway. J Mol Cell Cardiol 2014; 77: 42-52.
109. Gao S, Liu Z, Li H, Little PJ, Liu P, Xu S. Cardiovascular actions and therapeutic potential of tanshinone IIA. Atherosclerosis 2012; 220: 3-10.
110. Sun D, Shen M, Li J, et al. Cardioprotective effects of tanshinone IIA pretreatment via kinin B2 receptor-Akt-GSK-3beta dependent pathway in experimental diabetic cardiomyopathy. Cardiovasc Diabetol 2011; 10: 4.
111. Wang Y, Feng W, Xue W, et al. Inactivation of GSK-3β by metallothionein prevents diabetes-related changes in cardiac energy metabolism, inflammation, nitrosative damage, and remodeling. Diabetes 2009; 58: 1391-402.
112. Zhang Y, Wei L, Sun D, et al. Tanshinone IIA pretreatment protects myocardium against ischaemia/reperfusion injury through the phosphatidylinositol 3-kinase/Akt-dependent pathway in diabetic rats. Diabetes Obes Metab 2010; 12; 316-22.
113. Bohn T. Dietary factors affecting polyphenol bioavailability. Nutr Rev 2014; 72: 429-52.
114. Benzie IF, Choi SW. Antioxidants in food: content, measurement, significance, action, cautions, caveats, and research needs. Adv Food Nutr Res 2014; 71: 1-53.
115. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm 2007: 4: 807-18.
116. Novelle MG, Wahl D, Dieguez C, Bernier M, de Cabo R. Resveratrol supplementation: Where are we now and where should we go? Ageing Res Rev 2015; 21: 1-15.
117. Moreno Torres I, Sanchez AJ, Garcia-Merino A. Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis. Expert Rev Neurother 2014; 14: 1243-50.
118. Chagas MH, Zuardi AW, Tumas V, et al. An exploratory doubleblind trial. J Psychopharmacol 2014; 28: 1088-98.
119. Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia 2015; 56: 1246-51.